Article citationsMore>>

S. J. Knox, M. L. Goris, K. Trisler, R. Negrin, T. Davis, T. M. Liles, A. Grillo-López, P. Chinn, C. Varns, S. C. Ning, S. Fowler, N. Deb, M. Becker, C. Marquez and R. Levy, “Yttrium-90-Labeled Anti-CD20 Monoclonal Antibody Therapy of Recurrent B-Cell Lymphoma,” Clinical Cancer Research, Vol. 2, No. 3, 1996, pp. 457-470.

has been cited by the following article:

• TITLE: Incidental Uptake of In-111 Ibritumomab Tiuxetan in Surgically Treated Fracture

  AUTHORS: Hidenari Hirata, Makoto Nakagawa, Koichiro Abe, Takashi Okafuji, Kenji Shinozaki, Ilseung Choi, Naokuni Uike, Shuji Sakai

  KEYWORDS: In-111, Ibritumomab, Fracture, Lymphoma

  JOURNAL NAME: Advances in Molecular Imaging, Vol.1 No.1, April 22, 2011

  ABSTRACT: In-111 ibritumomab tiuxetan pretherapy imaging is performed prior to radioimmunotherapy with Y-90 ibritumomab tiuxetan in patients with lymphoma in order to estimate the biodistribution of the radiolabeled antibodies. We report the case of a 61-year-old woman with relapsed follicular lymphoma. In-111 ibritumomab tiuxetan pretherapy imaging showed tracer accumulation in a surgically treated fracture of the left calcaneus as well as in the involved lesions. The patient had fractured her left calcaneus 6 months before the radioimmunotherapy, and fracture of the left calcaneus without lymphoma involvement had been revealed operatively at that time. Clinical features and magnetic resonance imaging (MRI) indicated an inflammatory response in the left heel. We concluded that this inflammation played an important role in the uptake on pretherapy imaging. It should be kept in mind that the inflammation is a differential diagnosis of lymphoma involvement in In-111 ibritumomab tiuxetan pretherapy imaging. To the best of our knowledge, this is the first case report of In-111 ibritumomab tiuxetan uptake in a surgically treated fracture.